2nd Quarter - Report
THE D MAJOR GROUP for ALLERGAN INC (FORMERLY ACTAVIS INC )
Firm
Income
$48,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Monitor FDA funding for inspection of counterfeit medicines and separately, oversight of compounding medicines -- both as related to the FY 2018 Agriculture Appropriations bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Policy Analyst for Senate Republican Policy Committee |
| BRENDA REESE | Conference Coordinator for House Republican Conference |
Health Issues HCR
Advocate for voluntary best practices related to pharmaceutical pricing. Monitor H.R. 2430, the FDA Reauthorization Act of 2017; S. 934, the Food and Drug Reauthorization Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE MAJOR | Health Analyst for the Senate Republican Policy Committee |
| BRENDA REESE | Conference Coordinator for the House Republican Conference |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.